LDLR and metabolic dysfunction-associated steatohepatitis: Lu et al. demonstrated that AMI is an effective inhibitor of nonalcoholic steatohepatitis (NASH) in LDL receptor-deficient (LDLR−/−) mice with type 2 diabetes mellitus (T2DM) [30].